TRIAL DETAIL
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Withdrawn |
|||
Phase: |
1 |
Start Date 11/30/2014 |
Age of Trial (yrs) 10.9 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI) |
|||
Strategy: |
Block KIT + Block blood vessel growth |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
AMC1401 |
|||
Sponsor: |
Asan Medical Center |
|||
Patient Contact: |
Min-Hee Ryu, PhD
82-2-3010-5935 miniryu@amc.seoul.kr |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Seoul |
Songpa-gu |
138-736 |
Republic of Korea |